HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanomaterials Should Be Measured In Final Product Formulations – ICCR Report

This article was originally published in The Rose Sheet

You may also be interested in...

ICCR Finalizing Nanotech, Trace Impurities Reports Following 6th Meeting

Regulators from the U.S., the EU, Canada and Japan are working to finalize reports on nanomaterials, trace impurities and animal testing alternatives following the sixth meeting of the International Cooperation on Cosmetics Regulation. The regulators came to agreements on the reports at the July 10-13 meeting in Rockville, Md., and will hammer out the details before releasing the reports this fall.

U.S., EU Nanotech Guidances Demonstrate “Growing Consensus” – PCPC

The Personal Care Products Council’s Jay Ansell, VP of cosmetic programs, is optimistic about the direction regulators are taking and the consensus developing among scientific experts regarding the use of nanomaterials in cosmetics. However, challenges remain for firms faced with requirements under European law, and further harmonization is needed between international regulatory regimes, he suggests.

Toxicity, Transparency & Sunscreen Regs Among Top “Rose Sheet” Topics In 2011

“The Rose Sheet” analyzes the stories that garnered the most reader interest and had the highest impact on the personal-care industry in 2011. The top topics include Johnson & Johnson’s reformulation of its baby-care products and the establishment of the Safe Cosmetics Alliance.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts